An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves sNDA for Pediatric Achondroplasia Drug On October 20, the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for VOXZOGO® (vosoritide) to increase linear growth in pediatric patients with achondroplasia with open epiphyses (growth plates). […]
